Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial-Reference-Cited by-同舟云学术

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial

Published:2023-11-10 Issue:1 Volume:13 Page:85-105
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Schwedt Todd J.,Myers Oakes Tina M.^ORCID,Martinez James M.,Vargas Bert B.,Pandey Hitendra,Pearlman Eric M.,Richardson Diane R.,Varnado Oralee J.,Cobas Meyer Michael,Goadsby Peter J.

Funder

Eli Lilly and Company

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-023-00562-w.pdf

Reference41 articles.

1. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis—results from a placebo-controlled trial with propranolol as an active control. J Neurol. 2004;251:943–50.

2. Chowdhury D, Bansal L, Duggal A, et al. TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia. 2022;42:396–408.

3. Reuter U, Ehrlich M, Gendolla A, et al. Erenumab versus topiramate for the prevention of migraine—a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia. 2022;42:108–18.